NasdaqCM - Nasdaq Real Time Price USD

Monopar Therapeutics Inc. (MNPR)

Compare

25.35

+0.89

+(3.64%)

At close: January 10 at 4:00:02 PM EST

25.57

+0.22

+(0.87%)

After hours: January 10 at 6:38:07 PM EST

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.

Zacks 9 days ago

MNPR
+3.64%
AZN

CSTL
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025

“Past performance won’t guarantee future returns” is one of the first lessons in investing, a useful reminder that we can never tell what the future has in store. At the same time, a strong track record for a particular company can also suggest that the good times just might keep on rolling. So, what does it mean when a stock gains 1,000% or more in a single year? A jump of that magnitude signifies sustained outperformance – and investors will rightly wish to take a closer look. Wall Street’s an

TipRanks 12 days ago

MNPR
+3.64%
DAVE

DAVEW
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks 16 days ago

MNPR
+3.64%
ARQT

MSB.AX
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a priva

GlobeNewswire 22 days ago

MNPR
+3.64%
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved

GlobeNewswire last month

MNPR
+3.64%
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference. Presentation Details: Date: December 5, 2024Time: 10:30-10:55 am Eastern Time Locati

GlobeNewswire last month

MNPR
+3.64%
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results

GlobeNewswire 2 months ago

MNPR
+3.64%
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the

GlobeNewswire 2 months ago

MNPR
+3.64%
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fe

GlobeNewswire 2 months ago

MNPR
+3.64%
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no ass

GlobeNewswire 2 months ago

MNPR
+3.64%
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week

Key Insights Significant control over Monopar Therapeutics by individual investors implies that the general public has...

Simply Wall St. 2 months ago

MNPR
+3.64%
Monopar Therapeutics Secures License for Wilson Disease Treatment

Monopar Therapeutics Inc ( (MNPR) ) just unveiled an update. Monopar Therapeutics has secured an exclusive global license from Alexion Pharmaceuticals to develop and commercialize ALXN-1840, a promising treatment for Wilson disease, following a successful Phase 3 trial. The agreement entails an upfront payment of $4 million, equity in Monopar, and milestone payments up to $94 million, plus royalties. Despite regulatory challenges and the need for further funding, Monopar is focused on advancing

TipRanks 2 months ago

MNPR
+3.64%
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease that Alexion has progressed through a Phase 3 clinical trial that met its p

GlobeNewswire 2 months ago

MNPR
+3.64%
BMRN
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human

GlobeNewswire 2 months ago

MNPR
+3.64%
Monopar Therapeutics Expands Portfolio with New Patent Filing

Monopar Therapeutics Inc ( (MNPR) ) has shared an announcement. Monopar Therapeutics Inc. has expanded its intellectual property portfolio by filing a provisional patent for innovative therapeutic radiopharmaceuticals. The new patent covers a family of linkers designed to enhance stability and biodistribution, potentially leading to proprietary treatments for high-value cancer targets. This development reflects Monopar’s commitment to innovation and could pave the way for industry collaborations

TipRanks 2 months ago

MNPR
+3.64%
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims co

GlobeNewswire 2 months ago

MNPR
+3.64%
Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial

Monopar Therapeutics Inc ( (MNPR) ) has provided an update. Monopar Therapeutics Inc. is advancing the fight against cancer with the initiation of a Phase 1a clinical trial for its innovative radiopharmaceutical therapy, MNPR-101-Lu, targeting advanced cancers. The therapy is designed to selectively attack cancer cells by focusing on the urokinase plasminogen activator receptor (uPAR), common in various tumor types. With promising clinical and preclinical data, Monopar is optimistic about this p

TipRanks 3 months ago

MNPR
+3.64%
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) is now active and recruiting patients with advanced cancers. The Phase 1a trial is an open-label dose-escalation study of MNPR-101-Lu in patients with solid tumo

GlobeNewswire 3 months ago

MNPR
+3.64%
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans. MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase

GlobeNewswire 3 months ago

MNPR
+3.64%
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 9, 2024 at 7:00 a.m. ET. In person one-on-one meetings will take

GlobeNewswire 4 months ago

MNPR
+3.64%

Performance Overview

Return	MNPR	S&P 500
YTD	+6.29%	-1.35%
1-Year	+1,049.66%	+22.51%
3-Year	+44.03%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Monopar Therapeutics Inc. (MNPR)

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week

Monopar Therapeutics Secures License for Wilson Disease Treatment

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Therapeutics Expands Portfolio with New Patent Filing

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Performance Overview